Sweden Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The sweden cardiovascular devices market size is expected to grow from USD 340 million in 2025 to USD 353.53 million in 2026 and is forecast to reach USD 429.79 million by 2031 at 3.98% CAGR over 2026-2031. This report is Segmented by Device Type (Diagnostic and Monitoring Devices and Therapeutic and Surgical Devices), by Application (Coronary Artery Disease, Arrhythmia and More), by End User (Hospitals & Cardiac Centers, Ambulatory Surgical Centers and More). The Report Offers the Value (in USD) for all the Above Segments.

Sweden Cardiovascular Devices Market Trends and Insights

Rising prevalence of cardiovascular disease & ageing population

Cardiovascular disease accounts for one-quarter of Swedish mortality, with ischemic heart disease and stroke topping the list among seniors 65 +. The population segment aged 80 + is forecast to rise from 5.2% to 7.1% by 2030, prompting the National Board of Health and Welfare to estimate a 40% jump in cardiovascular interventions over the same horizon. Higher-than-European-average atrial fibrillation prevalence underpins demand for alternatives to oral anticoagulants, such as left atrial appendage (LAA) closure implants that gained selective reimbursement in late 2024. Sweden’s exhaustive registries - Patient Register, Cause of Death Register and SWEDEHEART - supply longitudinal real-world evidence that validates device effectiveness and informs procurement criteria. Taken together, a growing elderly cohort, strong epidemiologic tracking and universal access mandate continued expansion of the cardiovascular devices market.

National registries enabling real-world evidence adoption

The SWEDEHEART platform captures data from every catheterization laboratory and surgical center, tracking more than 200,000 procedures yearly and offering unmatched transparency for device outcomes. Registry-based randomized trials such as TASTE have validated the feasibility of large-scale pragmatic evidence generation without exorbitant costs, shortening the path to reimbursement in Sweden and abroad. Alignment with EuroHeart widens cross-border data harmonization, enhancing the export potential of Sweden-generated evidence for CE-marked products lakemedelsverket.se. TLV routinely references registry findings for value assessments, giving manufacturers that conduct Swedish trials a competitive edge in the cardiovascular devices market. As real-world data continues to inform clinical guidelines, registry infrastructure strengthens Sweden’s appeal as a development hub.

EU MDR Transition Increasing Time-to-market & Costs

Swedish manufacturers report 15-20% higher compliance expenditure for Class III cardiovascular products under EU MDR, eroding margins for niche devices. Although the Medical Products Agency engaged early with notified bodies, capacity bottlenecks have added 4-6 months to average approval cycles, delaying commercial launches and risking product withdrawals in low-volume categories. Smaller importers struggle to meet extensive clinical data requirements, constricting portfolio diversity in the cardiovascular devices market. Healthcare regions voice concern that certain specialized implants may disappear from procurement lists, potentially disrupting continuity of care. While Sweden participates in EU-wide coordination to clarify grey areas, lingering compliance uncertainty tempers investment in high-risk device R&D.

Other drivers and restraints analyzed in the detailed report include:

• Rapid hospital shift to minimally-invasive & transcatheter procedures
• Government incentives for digital health & remote cardiac monitoring
• Limited reimbursement for novel LAA & wearable devices

Segment Analysis

Therapeutic and surgical systems accounted for 62.98% of the cardiovascular devices market in 2025, underpinned by Sweden’s advanced cardiac surgery programs and mature reimbursement infrastructure that rewards long-term outcome data. The cardiovascular devices market size for therapeutic systems is projected to expand in line with a strong 3.92% CAGR as Karolinska’s 400 + annual TAVR caseload sets a Nordic benchmark and attracts regional referrals, supporting higher-value sales of delivery catheters, replacement valves and perfusion equipment. Hospitals prioritize drug-eluting stents, cardiac resynchronization devices and extracorporeal systems with proven cost-utility, a stance that favors established vendors such as Getinge AB, Medtronic and Abbott. Central procurement via SKR strengthens price discipline yet assures predictable demand for technologies that clear TLV’s health-economic hurdle.

Diagnostic and monitoring equipment represent the fastest-growing product class at 5.55% CAGR to 2031, aided by government incentives for remote monitoring, AI-enhanced electrocardiography and wearable sensors. The cardiovascular devices market is witnessing an influx of software-centric entrants leveraging Sweden’s electronic health record interoperability to embed analytics into routine care. Remote heart-failure monitoring platforms, reimbursed since 2024, have spurred regional tenders focusing on data security and integration features rather than hardware price alone. The Medical Products Agency’s six-month rapid-review track for breakthrough software further accelerates rollout, keeping diagnostic vendors firmly on investors’ radar.

Complete Report Scope:

• By Device Type
  • Diagnostic & Monitoring Devices
    • ECG Systems
    • Remote Cardiac Monitors
    • Cardiac MRI
    • Cardiac CT
    • Echocardiography / Ultrasound
    • Fractional Flow Reserve (FFR) Systems
  • Therapeutic & Surgical Devices
    • Coronary Stents
      • Drug-Eluting Stents
      • Bare-Metal Stents
      • Bioresorbable Stents
    • Catheters
      • PTCA Balloon Catheters
      • IVUS / OCT Catheters
    • Cardiac Rhythm Management Devices
      • Pacemakers
      • Implantable Cardioverter Defibrillators
      • Cardiac Resynchronization Therapy Devices
    • Heart Valves
      • TAVR / TAVI
      • Mechanical Valves
      • Tissue / Bioprosthetic Valves
    • Ventricular Assist Devices
    • Artificial Hearts
    • Grafts & Patches
    • Other Cardiovascular Surgical Devices
• By Application
  • Coronary Artery Disease
  • Arrhythmia
  • Heart Failure
  • Structural Heart Disease
  • Hypertension
  • Others
• By End-User
  • Hospitals & Cardiac Centers
  • Home-Care Settings
  • Ambulatory Surgical Centers

List of Companies Covered in this Report:

• Medtronic
• Abbott Laboratories
• Boston Scientific
• Getinge
• Edward Lifesciences
• Siemens Healthineers
• Koninklijke Philips
• GE HealthCare Technologies Inc.
• Johnson & Johnson (Biosense Webster & AcuRhythm)
• Terumo
• BIOTRONIK
• LivaNova
• Zoll Medical
• Beckton Dickinson
• Merit Medical Systems
• W. L. Gore & Associates
• Cook Group
• MicroPort
• Lepu Medical
• CryoLife
• CardioMech AS
• OssDsign AB

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support